COVID-19 hospitalizations, intensive care unit stays, ventilation and death among patients with immune mediated inflammatory diseases compared to controls

Lihi Eder¹, Ruth Croxford², Aaron M Drucker³, Arielle Mendel⁴, Bindee Kuriya⁵, Zahi Touma⁶, Sindhu R Johnson⁷, Richard Cook⁸, Sasha Bernatsky⁹, Nigil Haroon¹⁰, Jessica Widdifield¹¹

1. MD PhD, Women's College Research Institute, University of Toronto, Toronto, ON, Canada
2. MSc, ICES, Toronto, ON, Canada
3. MD, ScM, Women's College Research Institute, ICES, University of Toronto, Toronto, ON, Canada
4. MD, MSc, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec
5. MD, MPH, Sinai Health System, University of Toronto, Toronto, ON, Canada
6. MD, PhD, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
7. MD, PhD, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
8. PhD, University of Waterloo, Waterloo, ON, Canada
9. MD, PhD, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec
10. MD, PhD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
11. PhD, Sunnybrook Research Institute, ICES, Institute of Health Policy, Management, & Evaluation, University of Toronto, Toronto, ON, Canada

Corresponding author:

Dr Lihi Eder
 Women's College Research Institute, Rm 6326
 76 Grenville Street
 Toronto, ON, M5S 1B2
 Phone: 416-323-6400 ext 5108
lihi.eder@wchospital.ca

Conflict of Interest: The authors declare no conflicts of interest.

Word count: 3,117

COVID-19 Risk in IMIDs

Key words: Epidemiology, Hospitalization, Infection, Rheumatoid arthritis, Spondyloarthritis, Autoimmune diseases

Accepted Article

COVID-19 Risk in IMIDs

Abstract

Objective: To investigate COVID-19 hospitalization risk in patients with immune mediated inflammatory diseases (IMIDs) compared with matched non-IMID comparators from the general population.

Methods:

We conducted a population-based, matched cohort study using health administrative data from January to July 2020 in Ontario, Canada. Cohorts for each of the following IMIDs were assembled: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis, systemic autoimmune rheumatic diseases (SARDs), multiple sclerosis (MS), iritis, inflammatory bowel disease, polymyalgia rheumatica and vasculitis. Each patient was matched with 5 non-IMID comparators based on socio-demographic factors. We compared the cumulative incidence of hospitalizations for COVID-19 and their outcomes between IMID and non-IMID patients.

Results: A total of 493,499 IMID patients (417 hospitalizations) and 2,466,946 non-IMID comparators (1,519 hospitalizations) were assessed. The odds of being hospitalized for COVID-19 was significantly higher in patients with IMIDs compared with their matched non-IMID comparators (matched unadjusted Odds Ratio (OR) 1.37, adjusted OR 1.23). Significantly higher risk of hospitalizations was found in patients with iritis (OR 1.46), MS (OR 1.83), PsA (OR 2.20), RA (OR 1.42), SARDs (OR 1.47) and vasculitis (OR 2.07). COVID-19 hospitalizations were associated with older age, male sex, long-term care residence, multimorbidity, and lower income. The odds of complicated hospitalizations was 21% higher among all IMID versus matched non-IMID patients, but this association was attenuated after adjusting for demographic factors and comorbidities.

Conclusion: Patients with IMIDs were at higher risk of being hospitalized with COVID-19. This risk was explained in part by their comorbidities.

Introduction

Immune mediated inflammatory diseases (IMIDs) are complex disorders caused by a combination of genetic susceptibility and environmental factors(1). Population-based studies have shown that over 5% of the general population have a diagnosis of at least one IMID(2, 3). Patients with IMIDs are more susceptible to severe bacterial and viral infections(4-6). COVID-19 raises special concerns regarding its course and outcome among patients with IMIDs. It is unclear if COVID-19-related hyperinflammatory response, commonly leading to organ failure(7), is more common among patients with IMIDs who already have dysfunctional host immune systems. Multimorbidity, in particular respiratory, cardiovascular and renal diseases, has been associated with poor COVID-19 outcomes, and is prevalent among many patients with IMIDs(8-11). Finally, despite attempts to use immune modulating agents to treat severe COVID-19, some of these medications commonly used to manage IMIDs, including corticosteroids, and conventional and biologic immune modulating agents, have been associated with a higher risk of infections(12-14).

Despite multiple studies on COVID-19 risk in patients with IMIDs, population-based data remain scarce. A meta-analysis that included over over 60 publications evaluating COVID-19 hospitalizations in patients with IMIDs found considerable heterogeneity in the estimated risk(15). The majority of included studies were limited by their small size, selected population (single site, academic centres), incomplete outcome surveillance (self-report, survey) and a lack of matched non-IMID comparators. To date, only few population-based studies, mostly from European countries, found an increased risk of COVID-19 hospitalizations and mortality in patients with inflammatory joint diseases(16-19). However, information about the risk of severe COVID-19 among patients with IMIDs, especially in North American patients, remains limited.

COVID-19 Risk in IMIDs

To accurately estimate COVID-19 risk in IMIDs, the use of unselected population-based data with complete reporting of hospitalizations and careful adjustment of potential confounding factors is needed.

To address this gap in knowledge we used population-based, health administrative data from Ontario, Canada to investigate the risk of hospitalizations for and severe complications of COVID-19 in patients with IMIDs compared with matched non-IMID individuals from the general population.

Methods

Population and Setting

We conducted a population-based, matched cohort study using health administrative data among adult residents in Ontario from January 1, 2020 to July 31, 2020. Ontario comprises almost 40% of the Canadian population with 14.7 million individuals in 2020. The study population included adults aged 20 years and older who lived in the province on January 1, 2020. The first patient with COVID-19 in Ontario was reported on January 23, 2020. The Ontario Health Insurance Plan (OHIP) is a public, single-payer system that covers hospital admissions, physician services and procedures including SARS-CoV-2 tests for all Ontario residents(20). Health care encounters are recorded in administrative databases, which are linked using an encoded health insurance numbers that is unique to each Ontarian. These data are held securely and analyzed in linked, coded form at the ICES (www.ices.on.ca). The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, and approved by ICES' Privacy and Legal Office which does not require review by a research ethics board.

Data Sources

COVID-19 Risk in IMIDs

We used the OHIP physician service claims database to identify diagnosis codes of IMIDs and information about pre-existing comorbidities. These diagnoses are coded using a modification of the International Classification of Diseases Version 8 (ICD-8)(21). The Canadian Institute for Health Information's Discharge Abstract Database was used to identify diagnosis codes (ICD-10) of IMIDs and information about pre-existing comorbidities occurring during hospitalizations, and to identify study outcomes. Information about residential income quintile was identified using Statistics Canada's census data. Long-term care (LTC) residence was ascertained using the Complex Continuing Care-LTC database, which records the mandatory assessments on all LTC residents.

IMID Case Definitions

We used physician service claims and provincial hospitalization databases to assemble 10 non-mutually exclusive, cohorts of patients with the following IMIDs: rheumatoid arthritis, psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic autoimmune rheumatic diseases (SARDs) (including systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, inflammatory myositis, mixed connective tissue disease), multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica (PMR) and vasculitis (including giant cell arteritis and other types of vasculitides). When available, we used validated case definitions for the different IMIDs(22-26). For the remaining IMIDs that lacked prior case validation in Ontario, we used a similar approach that relied on a combination of physician visits for the specific IMID including at least one by a relevant specialist or at least one relevant ICD code given during a hospital admission. Of note, each patient may have been included in more than one cohort. Detailed information about the case definitions for inclusion in each cohort is shown in supplement 1.

COVID-19 Risk in IMIDs

Study entry required that a patient belonged to at least one of the above detailed IMIDs, be alive, be at least 20 years of age and living in Ontario on January 1, 2020. To ensure accurate baseline information, patients were also required to be eligible for OHIP coverage for at least 3 years prior to the study start date.

General Population Comparators

Each patient with IMID was matched with 5 patients without an IMID diagnosis based on age ($\pm$ 5 years), sex, area of residence (by Local Health Integration Network (LHIN)) or if they were residents of a LTC facility. All patients without IMIDs were required to be free of others IMIDs defined above.

Factors associated with hospitalizations

We assessed co-morbidities reported to be associated with severe COVID-19 in the general population to determine if they were associated with COVID-19 hospitalizations in IMIDs(27). Information about individual comorbid conditions at study entry was obtained from physician service claims and provincial hospitalization databases (supplement 2). The following co-morbidities were assessed: cardiovascular diseases, chronic obstructive lung disease (COPD)/asthma, chronic kidney disease, hypertension, diabetes mellitus, pulmonary emboli (PE) or deep venous thrombosis (DVT), dementia. Hospitalization due to respiratory tract infection (RTI) in the year prior to study entry, and the number of Johns Hopkins Aggregated Diagnosis Groups (ADGs) using the Johns Hopkins ACG[®] System Version 10) were also evaluated. Sociodemographic predictors include socioeconomic status (defined by census neighborhood income quintiles), rurality (classified as living in urban versus rural settings), and residing in a LTC facility.

COVID-19 Risk in IMIDs

Since measures of IMID severity and activity are not available in administrative databases, we used the number of physician claims for IMID diagnoses in the year prior to cohort entry, and IMID duration (defined from first IMID encounter to cohort entry) as surrogates of disease activity and disease burden.

COVID-19 hospitalizations

Patients who were admitted at least once for COVID-19 during the study period were those who had one of the following COVID-19 related ICD-10 codes in their discharge summary: U07.1 ('disease diagnosis of COVID-19 confirmed by laboratory testing') or U07.2 ('clinical of epidemiological diagnosis of COVID-19 where laboratory confirmation is inconclusive or not available'). These ICD-10 codes were introduced on February 24, 2020. The hospitalization outcomes were examined up to July 31, 2020. Only the first hospitalization for COVID-19 was considered for the analysis. As a secondary outcome, we assessed adverse COVID-19 hospitalization outcomes including admission to intensive care unit (ICU), ventilation or death during the admission. These were collectively termed 'complicated COVID-19 hospitalizations'. Since it was unclear whether all admissions due to COVID-19 were coded by the specific ICD-10 codes, we considered an alternative definition of COVID-19 hospitalization that included a combination of ICD codes associated with COVID-19 (e.g. pneumonia, acute respiratory distress syndrome) in patients who tested positive for SARS-CoV-2 (see supplement 3). This definition was included in a sensitivity analysis only.

Statistical analysis

Descriptive statistics were computed to characterize patients among those with and without IMIDs (at the time of study entry). We calculated standardized differences between the two

COVID-19 Risk in IMIDs

groups with a standardized difference larger than 0.10 indicating a clinically meaningful difference(28). Age- and sex-standardized incidence rates of COVID-19 hospitalizations (along with 95% confidence intervals (CI)) were reported for each IMID group and then over-all using the 2016 Ontario population for direct age and sex standardization to enable comparisons across IMID groups. Patients were followed from study entry (January 2020) until they experienced any of the following outcomes (whichever came first): end of study (July 31, 2020), death or first COVID-19 hospitalization.

We used multivariable logistic regression to model the probability of hospitalization for COVID-19 and for having complicated COVID-19 hospitalization between patients with IMIDs versus patients without IMIDs, adjusting for sociodemographic factors and comorbidities and accounting for matching. Each regression model included membership in an IMID group as the primary covariate and the following additional covariates: age, sex, residing in LTC, number of comorbidities (by ADGs), socioeconomic status and rurality. Then, among patients with IMIDs, we estimated adjusted odds ratios (OR) along with 95% CI to compare COVID-19 hospitalizations among the different IMIDs, adjusting for the same covariates as above in addition to surrogates of disease activity, disease duration, and comorbidities.

Results

A total of 493,499 adults with IMIDs and 2,466,946 matched non-IMID comparators who lived in Ontario in January 2020 were included in the study. Overall, the mean (SD) age of IMID patients was 58.3 (17) years and 60.7% were females (Table 1).

COVID-19 hospitalizations in patients with IMIDs

COVID-19 Risk in IMIDs

A total of 417 patients with IMIDs (0.08%) and 1,519 matched patients without IMIDs were hospitalized for COVID-19 during the study period (0.06%). RA (32.1% of the hospitalizations) and psoriasis (27.6% of the hospitalizations) were the most common IMID diagnoses among hospitalized. Our sensitivity analysis using an alternative definition for COVID-19 hospitalizations identified a similar number of admissions (417 in IMIDs and 1,530 in non-IMIDs), therefore, the primary definition of COVID-19 hospitalization was used for all analyses. The overall age- and sex-standardized incidence of COVID-19 hospitalizations was higher in patients with IMIDs than in patients without IMIDs (6.44 (95% CI 5.78, 7.16) vs. 4.77 (95% CI 4.51, 5.04) patients per 10,000 population, respectively). The highest absolute rates of hospitalizations were found in patients with vasculitis (17.99 per 10,000 population), MS (16.68 per 10,000 population) and PMR (10.06 per 10,000 population) (Figure 1).

In our unadjusted analysis, patients with IMIDs were more likely to be hospitalized for COVID-19 than matched non-IMID patients (matched unadjusted OR 1.37 (95% CI 1.23, 1.53), Figure 2). This association was somewhat attenuated after adjusting for demographic factors and comorbidities (matched adjusted OR 1.23 (95% CI 1.10, 1.37). Numerically, higher odds of hospitalizations were found across all IMIDs (Figure 2). In the unadjusted model, patients with iritis, MS, PsA, RA, SARDs and vasculitis had higher probability of being hospitalized versus with their matched non-IMID comparators. Hospitalization risk remained significantly higher in patents with RA, PsA and MS after adjusting for demographic factors and comorbidities in the multivariable analysis.

Risk factors for COVID-19 hospitalizations

COVID-19 Risk in IMIDs

Risk factors for COVID-19 hospitalizations among patients with IMIDs (Table 2), included older age, male sex, residing in LTC facility, and lower socio-economic status. In addition, the following co-morbidities in patients with IMIDs were significantly associated with COVID-19 hospitalizations: dementia, chronic kidney disease, hospitalization due to respiratory tract infection in the year prior to study entry, cardiovascular disease, diabetes, hypertension and COPD/asthma. Regarding IMID-related factors, a weak, but significant association was found between shorter IMID duration and hospitalization risk.

Complicated COVID-19 hospitalizations

A total of 163 out of the 417 (39%) patients with IMIDs who were hospitalized for COVID-19 experienced complications during their admission. The proportion of those without IMIDs who experienced a complicated hospitalization was numerically higher however not different statistically (676 out of 1,519 hospitalizations (44.5%), $p=0.05$). The proportions of in-hospital deaths among those hospitalized with COVID-19 were similar in patients with and without IMIDs (IMIDs: 101 out of 417 (24.2%) vs. non-IMIDs: 388 out of 1,519 (25.5%), $p=0.3$). Considering the entire study population, patients with IMIDs were at higher risk for complicated COVID-19 hospitalizations (matched unadjusted OR 1.21 (95% CI 1.02, 1.43)) compared with their matched non-IMID comparators in our univariate analysis, which attenuated after adjustment (matched adjusted OR 1.09 (95% CI 0.91, 1.29); Figure 3). In the unadjusted regression analysis, significant risk for complicated COVID-19 hospitalizations were found in patients with MS (OR 2.09) and RA (OR 1.39) compared with matched non-IMID comparators. The risk for complicated COVID-19 hospitalizations remained elevated in the fully adjusted

COVID-19 Risk in IMIDs

model in patients with MS (OR 2.03). In the remaining IMID subgroup the confidence intervals were wide and crossed 1.

Discussion

In one of the largest population-based study to date, we found that patients with IMIDs were at higher risk of being hospitalized for COVID-19. This association was only partially explained by comorbid conditions highlighting the independent risk for experiencing severe COVID-19 associated with having a diagnosis of IMID.

COVID-19 continues to pose major challenges to the healthcare system leading to high rates of hospitalizations as well as in-hospital complications and death. IMID patients with their unique characteristics deserve special attention focusing on their overall risk of experiencing a severe course of COVID-19. Population-based information regarding the risk of severe COVID-19 remains limited. A meta-analysis that summarized six small case-control studies concluded that the risk of COVID-19 hospitalizations were similar in patients with and without IMIDs(15). In contrast, recent population-based studies from Denmark and Sweden found that the risk of COVID-19 hospitalizations was increased by 46% and 32%, respectively, in patients with inflammatory rheumatic diseases compared with the general population with the highest risk found in patients with RA(16-17). Another study from the US that included patients who were diagnosed with COVID-19 showed that a diagnosis of IMIDs was associated with a 14% higher risk of being hospitalized and a 32% higher risk for ICU admission than patients without IMIDs(18). We found a 37% higher risk of hospitalizations in patients with IMIDs (23% higher after adjusting for comorbidities and sociodemographic factors) which is in line with previous reports from Europe. Our study results further expand on the differential risk of hospitalizations

COVID-19 Risk in IMIDs

across IMID sub-groups. While hospitalization risk was numerically higher across all IMIDs, several disease groups were associated with significantly higher risk of being hospitalized compared with their matched non-IMID comparators. Such IMID groups (RA, SARDs, MS, vasculitis, PsA and iritis) often require treatment with systemic corticosteroids and/or are associated with high burden of complex comorbidities, which may partly explain this association. Despite their proven benefit in improving outcomes of severe COVID-19 in the general population, systemic corticosteroids have been associated with a higher risk of severe COVID-19 in patients with IMIDs(29-32). Multimorbidity was a major contributing factor to the risk of hospitalization in our study with a number of chronic comorbid conditions, including cardiovascular, respiratory and kidney diseases as well as hypertension, diabetes and dementia, contributing to this risk. These comorbid conditions tend to be associated with IMIDs directly due to the disease process, due to shared risk factors or secondary to treatment used to manage IMIDs. Previous studies in the general population and among IMID patients identified some of these comorbidities as risk factors for severe COVID-19 disease(27, 29, 31, 33). Thus, our results suggest an overall higher but differential COVID-19 hospitalization risk among patients with IMIDs is only partially explained by their higher co-morbidity burden.

It remains controversial whether patients with IMIDs are at higher risk of experiencing in-hospital complications compared to non-IMID patients. While it has been suggested that patients with IMIDs are at higher risk for experiencing complicated hospitalizations(34) other studies have not yet found such an association (35, 36). We found 21% higher odds of complicated hospitalizations among patients with IMIDs when considering the entire study population regardless of whether they were admitted. However, among those admitted for COVID-19, the overall proportion of complicated hospitalizations was similar in patients with and without

COVID-19 Risk in IMIDs

IMIDs, as were the proportions of those who required ICU admission and those dying during the admission. The similar hospitalization outcomes in IMID and non-IMID patents are notable given the higher number of comorbidities in the former group. The high proportion of complicated admissions among patients with IMIDs who were admitted, reaching 39% of all admitted patients is noteworthy. These figures are in accordance with previous studies that reported 32-48% of IMID patients experiencing in-hospital complications and 13-22% dying during their admission(17, 33, 34, 37), reflecting the first wave of the pandemic. It remains to be seen whether the rates of these adverse outcomes have changed in subsequent waves of the disease following changes in the approach to treatment of hospitalized patients with COVID-19.

A major strength of our study is the centralized data resource in the setting of a public health system with access to hospital care for the entire population. To our knowledge this is one of the largest studies published to date on COVID-19 hospitalizations in patients with IMIDs. The large cohort of patients with IMIDs and matched non-IMIDs and complete reporting of hospitalizations in our study, avoided some of the major limitations of previous studies thus making our results both robust and highly generalizable. We acknowledge several limitations. First, the case definitions are based on diagnosis coding from physicians and hospital records used for administrative purposes, so misclassification of IMID diagnoses is possible. When available, we used validated case definitions that showed high performance in previous studies and we used a similar approach to identify IMIDs without validated case definitions. The population prevalence and demographic characteristics of the different IMIDs in our study is in line with what would be expected, providing further face validity to the accuracy of our case definitions. Second, since outpatient prescription medications in Ontario are funded only for patients aged 65 years or older, social assistance recipients, and residents who have very high

COVID-19 Risk in IMIDs

drug costs relative to their income, we did not include medication data in our study. Therefore, we could not evaluate the impact of these immunosuppressive or other medications on hospitalizations. Some studies suggest that the risk of severe COVID-19 is associated with the use of some immune modulating agents, such as corticosteroids (higher risk) and TNF inhibitors (lower risk)(29-31), however, other studies could not find such associations(17, 33). Lastly, due to delays in reporting we do not have information about patients who died outside of the hospital, either before they could be admitted or after they were discharged from the hospital.

In summary, we found that the risk of severe COVID-19 requiring hospitalization is increased in patients with IMIDs compared with non-IMID patients. This risk is partially explained by the higher burden of comorbidities in patients with IMIDs and varies across different IMIDs. Older age, number and severity of comorbidities and sociodemographic factors contribute to hospitalization risk among patients with IMIDs as they do in the general population. Our results suggest that patients with IMIDs should be considered a high-risk group for developing severe COVID-19. These data support advocacy and public health measures to reduce the risk of infection, such as promoting COVID-19 vaccinations among patients with IMIDs(38, 39).

References

1. Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoimmune diseases co-occurring within individuals and within families: A systematic review. *Epidemiology* 2006;17:202-17.
2. Sardu C, Cocco E, Mereu A, et al. Population based study of 12 autoimmune diseases in sardinia, italy: Prevalence and comorbidity. *PLoS One* 2012;7:e32487.
3. Eaton WW, Pedersen MG, Atladottir HO, Gregory PE, Rose NR, Mortensen PB. The prevalence of 30 icd-10 autoimmune diseases in denmark. *Immunol Res* 2010;47:228-31.
4. Kuo CF, Burns PB, Chen JS, Wang L, Chung KC. Risk of preventable hospitalization before and after diagnosis among rheumatoid arthritis patients compared to non-rheumatoid arthritis controls. *Joint Bone Spine* 2020;87:149-56.
5. Kedves M, Kosa F, Kunovszki P, et al. Large-scale mortality gap between sle and control population is associated with increased infection-related mortality in lupus. *Rheumatology (Oxford)* 2020;59:3443-51.
6. Yiu ZZN, Parisi R, Lunt M, et al. Risk of hospitalization and death due to infection in people with psoriasis: A population-based cohort study using the clinical practice research datalink. *Br J Dermatol* 2021;184:78-86.
7. Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in covid-19. *Theranostics* 2021;11:316-29.
8. McQueenie R, Nicholl BI, Jani BD, et al. Patterns of multimorbidity and their effects on adverse outcomes in rheumatoid arthritis: A study of 5658 uk biobank participants. *BMJ Open* 2020;10:e038829.
9. Lubrano E, Scryfallano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis - a perspective. *Expert Rev Clin Immunol* 2020;16:963-72.
10. England BR, Roul P, Yang Y, et al. Burden and trajectory of multimorbidity in rheumatoid arthritis: A matched cohort study from 2006 to 2015. *Ann Rheum Dis* 2020.
11. Gunderson TM, Myasoedova E, Davis JM, 3rd, Crowson CS. Multimorbidity burden in rheumatoid arthritis: A population-based cohort study. *J Rheumatol* 2021; 48:1648-1654.
12. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule jak inhibitors in rheumatoid arthritis. *Rheumatology (Oxford)* 2019;58:1755-66.
13. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. *Lancet* 2015;386:258-65.
14. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with crohn's disease: More than 5 years of follow-up in the treat registry. *Am J Gastroenterol* 2012;107:1409-22.
15. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of covid-19 in patients with autoimmune diseases: A systematic review and meta-analysis. *Ann Rheum Dis* 2021; 80: 384-391.
16. Bower H, Frisell T, Di Giuseppe D, et al. Impact of the covid-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: A nationwide swedish cohort study. *Ann Rheum Dis* 2021; 80: 1086-93.

17. Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of covid-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from denmark. *Rheumatology (Oxford)* 2021;60:SI59-SI67.
18. D'Silva KM, Jorge A, Cohen A, et al. Covid-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A us multicenter, comparative cohort study. *Arthritis rheumatol* 2021;73:914-20.
19. Peach E, Rutter M, Lanyon P, et al. Risk of death among people with rare autoimmune diseases compared with the general population in england during the 2020 covid-19 pandemic. *Rheumatology (Oxford)* 2021;60:1902-9.
20. Health care in ontario: Ontario ministry of health and long-term care;. [cited 24/12/2021]; Available from: <https://www.ontario.ca/page/health-care-ontario>.
21. Who. Classification of diseases (icd) geneva: World health organization (who). [cited 24/12/2021]; Available from: <https://www.who.int/classifications/icd/en/>
22. Eder L, Widdifield J, Rosen CF, et al. Identifying and characterizing psoriasis and psoriatic arthritis patients in ontario administrative data: A population-based study from 1991 to 2015. *J Rheumatol* 2020; 47: 1644-51.
23. Widdifield J, Bernatsky S, Paterson JM, et al. Accuracy of canadian health administrative databases in identifying patients with rheumatoid arthritis: A validation study using the medical records of rheumatologists. *Arthritis Care Res (Hoboken)* 2013;65:1582-91.
24. Barra L, Pope JE, Pequeno P, et al. Incidence and prevalence of giant cell arteritis in ontario, canada. *Rheumatology (Oxford)* 2020;59:3250-8.
25. Benchimol EI, Guttman A, Mack DR, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from ontario, canada. *J Clin Epidemiol* 2014;67:887-96.
26. Widdifield J, Ivers NM, Young J, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in ontario, canada. *Mult Scler* 2015;21:1045-54.
27. Ko JY, Danielson ML, Town M, et al. Risk factors for covid-19-associated hospitalization: Covid-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. *Clin Infect Dis* 2021; 72: e695-e703.
28. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. *Bmj* 2005;330:960-2.
29. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for covid-19 in people with rheumatic disease: Data from the covid-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis* 2020;79:859-66.
30. Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases - case series from new york. *N Engl J Med* 2020;383:85-8.
31. Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated with covid-19-related death in people with rheumatic diseases: Results from the covid-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis* 2021; 80: 930-42.
32. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19. *N Engl J Med* 2021;384:693-704.

COVID-19 Risk in IMIDs

33. Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with covid-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. *Ann Rheum Dis* 2020;79:1544-9.
34. D'Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (covid-19) and rheumatic disease: A comparative cohort study from a us 'hot spot'. *Ann Rheum Dis* 2020;79:1156-62.
35. Monreal E, Sainz de la Maza S, Fernandez-Velasco JI, et al. The impact of immunosuppression and autoimmune disease on severe outcomes in patients hospitalized with covid-19. *J Clin Immunol* 2021; 41: 315-23.
36. Faye AS, Lee KE, Laszkowska M, et al. Risk of adverse outcomes in hospitalized patients with autoimmune disease and covid-19: A matched cohort study from new york city. *J Rheumatol* 2021; 48: 454-62.
37. Freitas Nunez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to covid-19 in patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* 2020;79:1393-9.
38. Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the covid-19 pandemic: Version 1. *Arthritis Rheumatol* 2020;72:1241-51.
39. Curtis JR, Johnson SR, Anthony DD, et al. American college of rheumatology guidance for covid-19 vaccination in patients with rheumatic and musculoskeletal diseases - version 1. *Arthritis Rheumatol* 2021; 73: 1093-1107.

COVID-19 Risk in IMIDs

Funding: The study is supported by ICES (formerly known as the Institute for Clinical Evaluative Sciences), which is funded by the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Parts of this material are based on data and information compiled and provided by MOH and the Canadian Institute for Health Information. The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding or data sources; no endorsement is intended or should be inferred. Dr. Widdifield receives support from the Arthritis Society Stars Career Development Award (STAR-19-0610). Dr. Bernatsky is a James McGill Professor of Medicine, Dr. Johnson is supported by a New Investigator Award from the Canadian Institutes of Health Research and the Gurmej Kaur Dhanda Scleroderma Research Award

Conflict of interests:

Lihi Eder- research/educational grants from Abbvie, UCB, Pfizer, Eli Lilly; consulting fees from Abbvie, Pfizer, Novartis, UCB

Bindee Kuriya - Rheumatology advisory board member for Pfizer, Gilead, Abbvie

Sindhu Johnson - Grants/contracts from Boehringer Ingelheim, Corbus; Consulting fee from Boehringer Ingelheim, Corbus; member in the ACR COVID-19 Clinical Guidance Task Force and ACR COVID-19 Vaccination Guidance Task Force.

The remaining authors have no conflicts to disclose.

Figure legends

Figure 1. Age- and Sex-standardized cumulative incidence of COVID-19 hospitalizations by IMID groups

Figure 2. The association between IMIDs and COVID-19 hospitalizations by logistic regression showing the odds ratio and 95% confidence intervals for the different IMID groups.

Figure 3. The association between IMIDs and complicated hospitalization by logistic regression showing the odds ratio and 95% confidence intervals for the different IMID groups.

Figure 1 - Age- and Sex-Standardized Cumulative Incidence of COVID-19
Hospitalizations by IMID group*

Figure 2 - The Association between IMIDs and COVID-19 Hospitalizations by Logistic Regression*

IMIDs group	Unadjusted OR (95% CI)	Adjusted OR (95% CI)*
All IMID	1.37 (1.23, 1.53)	1.23 (1.10, 1.37)
Vasculitis	2.07 (1.06, 4.06)	1.42 (1.33, 1.51)
SARDs	1.47 (1.06, 2.03)	1.23 (0.88, 1.72)
RA	1.42 (1.18, 1.72)	1.24 (1.02, 1.50)
PsA	2.20 (1.08, 4.47)	2.16 (1.03, 4.49)
Psoriasis	1.15 (0.94, 1.41)	1.04 (0.85, 1.27)
PMR	1.33 (0.83, 2.11)	1.11 (0.68, 1.79)
MS	1.83 (1.29, 2.57)	1.77 (1.25, 2.52)
Iritis	1.46 (1.07, 2.00)	1.32 (0.96, 1.81)
IBD	1.40 (0.88, 1.23)	1.17 (0.72, 1.88)
AS	1.57 (0.96, 2.55)	1.36 (0.83, 2.24)

*Adjusted for age, sex, LTC, income, ADG score, rurality

Figure 3 - The Association between IMIDs and Complicated COVID-19 Hospitalizations by Logistic Regression*

IMIDs group	Unadjusted OR (95% CI)	Adjusted OR (95% CI)*
All IMID	1.21 (1.02, 1.43)	1.09 (0.91, 1.29)
Vasculitis	0.94 (0.27, 3.22)	0.85 (0.24, 2.96)
SARDs	1.04 (0.59, 1.86)	0.89 (0.50, 1.61)
RA	1.39 (1.04, 1.86)	1.24 (0.92, 1.66)
PsA	1.36 (0.38, 4.49)	1.20 (0.33, 4.43)
Psoriasis	0.91 (0.65, 1.27)	0.84 (0.60, 1.18)
PMR	0.93 (0.44, 1.95)	0.76 (0.34, 1.70)
MS	2.09 (1.20, 3.62)	2.03 (1.15, 3.60)
Iritis	1.37 (0.86, 2.20)	1.27 (0.79, 2.04)
IBD	1.22 (0.59, 2.52)	0.95 (0.44, 2.06)
AS	1.48 (0.67, 3.26)	1.34 (0.60, 2.98)

*Adjusted for age, sex, LTC, income, ADG score, rurality

Table 1 – Characteristics of the study population at baseline						
	All participants		COVID-19 Hospitalization		Complicated COVID-19 Hospitalization*	
	IMID N=493,499	Non-IMID N=2,466,946	IMID N=417	Non-IMID N=1,519	IMID N=163	Non-IMID N=676
Disease category						
AS	28,913 (5.6%)		21 (5%)		8 (4.9%)	
IBD	54,264 (11%)		23 (5.5%)		9 (5.5%)	
Iritis	42,278 (8.6%)		50 (12%)		22 (13.5%)	
MS	31,687 (6.4%)		44 (10.6%)		18 (11%)	
PMR	15,583 (3.2%)		22 (5.3%)		8 (4.9%)	
Psoriasis	173,984 (35.3%)		115 (27.6%)		40 (24.5%)	
PsA	15,824 (3.2%)		11 (2.6%)		<6	
RA	134,964 (27.3%)		134 (32.1%)		59 (36.2%)	
SARDs	52,494 (10.6%)		46 (11%)		14 (8.6%)	
Vasculitis	6,128 (1.2%)		12 (2.9%)		<6	
Age (SD)	58.3 (17)	58 (16.9)	72 (14.5)	72.7 (14.3)	74.8 (14.3)	74.9 (13.3)
Sex: Female (%)	299,583 (60.7%)	1,525,671(60.4%)	236 (56.6%)	859 (56.6%)	81 (49.7%)	360 (53.3%)
Residential area: Urban (%)	449,392 (91.1%)	2,244,307 (91.0%)	405 (97.1%)	1,484 (97.7%)	157 (96.3%)	660 (97.6%)
Live in LTC (%)	6,687 (1.4%)	32,898 (1.3%)	70 (16.8%)	341 (22.4%)	28 (17.2%)	182 (26.9%)
Number of ADG (SD)	9.2 (4.4)	6.8 (4.3)	13.1 (4.7)	10.6 (5)	13.4 (4.6)	10.4 (5.1)
IMIDs duration (SD)	12.6 (7.4)		12.8 (7.6)		12.6 (7.8)	
Comorbidities (%)						
Hypertension	214,600 (43.5%)	932,556 (37.8%)	315 (75.5%)	1,093 (72%)	134 (82.2%)	512 (75.7%)
Diabetes	424,115 (17.2%)	97,578 (19.8%)	183 (43.9%)	670 (44.1%)	80 (49.1%)	322 (47.6%)
Cardiovascular disease	16,582 (3.4%)	57,658 (2.3%)	62 (14.9%)	179 (11.8%)	34 (20.9%)	90 (13.3%)
PE/DVT	2,564 (0.5%)	6,698 (0.3%)	9 (2.2%)	22 (1.4%)	<6	8 (1.2%)
COPD or asthma	147,159 (29.8%)	542,051 (22.0%)	190 (45.6%)	527 (34.7%)	72 (44.2%)	237 (35.1%)
Chronic kidney disease	21,503 (4.4%)	62,177 (2.5%)	73 (17.5%)	215 (14.2%)	42 (25.8%)	116 (17.2%)

Dementia	16,453 (3.3%)	71,301 (2.9%)	104 (24.9%)	408 (26.9%)	50 (30.7%)	214 (31.7%)
Hospitalization due to RTI*	5,068 (1.0%)	12,742 (0.5%)	29 (7%)	78 (5.1%)	15 (9.2%)	40 (5.9%)
<p>Bolded – standardized difference comparing IMIDs to their matched controls ≥ 0.1 and $p < 0.05$; *ICU admission/mechanical ventilation/in-hospital death</p> <p>AS – ankylosing spondylitis; COPD – chronic obstructive lung disease; DVT – deep vein thrombosis; IBD – inflammatory bowel disease; IMIDs – Immune mediated inflammatory disease; LTC – long term care; MS – multiple sclerosis; PE – pulmonary emboli; PsA – psoriatic arthritis; PMR – polymyalgia rheumatica; RA – rheumatoid arthritis; RTI – respiratory tract infection; SARDs – systemic autoimmune rheumatic disease;</p> <p>*In the year prior to study entry.</p>						

Table 2 – Factors associated with COVID-19 hospitalizations among patients with IMIDs by multivariable logistic regression*		
Variable	OR	CI 95%
Age (per 10-year increase)	1.35	1.24, 1.47
Sex: Male	1.39	1.14, 1.69
Residing in LTC facility	3.26	2.30, 4.62
Socioeconomic status (by income)		
• Quintile 1 (lowest)	Referent	
• Quintile 2	0.87	0.67, 1.14
• Quintile 3	0.69	0.52, 0.93
• Quintile 4	0.50	0.36, 0.69
• Quintile 5 (highest)	0.60	0.44, 0.82
Co-morbidities		
• Cardiovascular diseases	1.62	1.20, 2.17
• COPD/Asthma	1.36	1.12, 1.66
• Chronic kidney disease	1.94	1.47, 2.55
• DVT/PE	1.74	0.89, 3.40
• Dementia	2.19	1.61, 2.99
• Hospitalization due RTI	1.73	1.13, 2.64
• Hypertension	1.46	1.12, 1.91
• Diabetes	1.60	1.30, 1.96
Number of physician visits with IMID diagnosis		
• 0	Referent	
• 1-3	0.88	0.68, 1.14
• >3	1.29	0.98, 1.70
Duration of IMID (years)	0.986	0.972, 0.998
CI- Confidence Interval; COPD – chronic obstructive lung disease; DVT – deep vein thrombosis; IMIDs – Immune mediated inflammatory disease; LTC – long term care; OR – Odds Ratio; PE – pulmonary emboli; RTI – respiratory tract infection; *Adjusted for IMID category		